Novartis: FDA approves preventive treatment of migraine

(CercleFinance.com) - The US Food and Drug Administration (FDA) has approved Amgen and Novartis' Aimovig for the preventive treatment of migraine in adults.


The drug blocks the calcitonin gene-related peptide receptor, which is believed to play a critical role in migraine, Novartis said on Friday.

Aimovig is expected to be available to patients in the US within one week.

Its list price will be 575 dollars for once-monthly 70 or 140 mg single-use pre-filled autoinjectors, or 6,900 dollars annually.

In 2015, Novartis and Amgen entered into a global collaboration to develop and market pioneering treatments in the field of migraine and Alzheimer's disease.

Copyright (c) 2018 CercleFinance.com. All rights reserved.